Search research articles
Contact Us
Filters
Showing results (261-270 of 273) with videos related to
Page
of 28
Sort By:
Clinical and Translational Radiation Oncology
|
March 30, 2018
Retrospective methods to estimate radiation dose at the site of breast cancer development after Hodgkin lymphoma radiotherapy
Nicola S Russell, Inge M Krul, Anna M van Eggermond, et al.
Journal of Immunological Methods
|
March 29, 2021
Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients
A M Cook, S E Faustini, L J Williams, et al.
BMJ Open
|
April 9, 2025
SMALL: open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer-protocol for a phase III randomised multicentre trial
Kenneth Elder, Charlotte Coles, David Dodwell, et al.
Journal of Medicinal Chemistry
|
April 18, 2003
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK
Mark A Seefeld, William H Miller, Kenneth A Newlander, et al.
The British Journal of Radiology
|
January 24, 2024
Evidence-informed recommendations on managing breast screening atypia: perspectives from an expert panel consensus meeting reviewing results from the Sloane atypia project
Karoline Freeman, Alice Mansbridge, Hilary Stobart, et al.
Molecular Cancer Therapeutics
|
July 31, 2021
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
Joanne M Munck, Valerio Berdini, Luke Bevan, et al.
Journal of Medicinal Chemistry
|
June 27, 2024
Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase
Nick Palmer, Christopher Agnew, Caroline Benn, et al.
Antimicrobial Agents and Chemotherapy
|
September 18, 2002
Discovery of a novel and potent class of FabI-directed antibacterial agents
David J Payne, William H Miller, Valerie Berry, et al.
Journal of Medicinal Chemistry
|
August 13, 2021
Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2
Tom D Heightman, Valerio Berdini, Luke Bevan, et al.
Journal of Medicinal Chemistry
|
May 19, 2018
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2
Tom D Heightman, Valerio Berdini, Hannah Braithwaite, et al.
Page
of 28
Search research articles
Search
Showing results (261-270 of 273) with videos related to
Sort By:
Page
of 28
Clinical and Translational Radiation Oncology
|
March 30, 2018
Retrospective methods to estimate radiation dose at the site of breast cancer development after Hodgkin lymphoma radiotherapy
Nicola S Russell, Inge M Krul, Anna M van Eggermond, et al.
Journal of Immunological Methods
|
March 29, 2021
Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients
A M Cook, S E Faustini, L J Williams, et al.
BMJ Open
|
April 9, 2025
SMALL: open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer-protocol for a phase III randomised multicentre trial
Kenneth Elder, Charlotte Coles, David Dodwell, et al.
Journal of Medicinal Chemistry
|
April 18, 2003
Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK
Mark A Seefeld, William H Miller, Kenneth A Newlander, et al.
The British Journal of Radiology
|
January 24, 2024
Evidence-informed recommendations on managing breast screening atypia: perspectives from an expert panel consensus meeting reviewing results from the Sloane atypia project
Karoline Freeman, Alice Mansbridge, Hilary Stobart, et al.
Molecular Cancer Therapeutics
|
July 31, 2021
ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK
Joanne M Munck, Valerio Berdini, Luke Bevan, et al.
Journal of Medicinal Chemistry
|
June 27, 2024
Fragment-Based Discovery of a Series of Allosteric-Binding Site Modulators of β-Glucocerebrosidase
Nick Palmer, Christopher Agnew, Caroline Benn, et al.
Antimicrobial Agents and Chemotherapy
|
September 18, 2002
Discovery of a novel and potent class of FabI-directed antibacterial agents
David J Payne, William H Miller, Valerie Berry, et al.
Journal of Medicinal Chemistry
|
August 13, 2021
Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2
Tom D Heightman, Valerio Berdini, Luke Bevan, et al.
Journal of Medicinal Chemistry
|
May 19, 2018
Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2
Tom D Heightman, Valerio Berdini, Hannah Braithwaite, et al.
Page
of 28